As of Q4'25, Johnson & Johnson ( JNJ ) reported a diluted EPS of 2.1 USD, with year-over-year EPS growth at 0.49%. This marks a moderate improvement from the previous quarter and reflects a stabilization in earnings after significant fluctuations in prior periods. Over the period from Q1'23 to Q4'25, the company's EPS showed considerable volatility, peaking sharply at 10.21 USD in Q3'23 before normalizing to a range between 1.1 USD and 4.54 USD in subsequent quarters. Year-over-year EPS growth rates also varied widely, with notable spikes such as 45.67% in Q1'24 and periods of negative growth, particularly in Q3'24 (-89.13%). Overall, the trend suggests that while JNJ experienced some exceptional quarters, its earnings have recently stabilized at a more consistent level.